Filippo Rossignoli

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity”.

Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity

Science Translational Medicine(2023)10.1126/scitranslmed.abo4778

N/A

0.648DataRank · unranked

74 citations

Clemens Reinshagen, Thijs van Schaik, Filippo Rossignoli, Paulo Borges, Natalia Claire Mendonca +6 more

Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice

Frontiers in Immunology(2024)10.3389/fimmu.2023.1324618

N/A

0.396DataRank · unranked

13 citations

Thijs van Schaik, Kok‐Siong Chen, Filippo Rossignoli, Paulo Borges, Vladimir Vrbanac +3 more

NK cells in the brain: implications for brain tumor development and therapy

Trends in Molecular Medicine(2022)10.1016/j.molmed.2021.12.008

N/A

0DataRank · unranked

33 citations

Filippo Rossignoli, Khalid Shah, Agisilaos Balatsoukas

Developing and characterizing a two-layered safety switch for cell therapies

Cancer Biology & Therapy(2023)10.1080/15384047.2023.2232146

N/A

0DataRank · unranked

8 citations

Danielle Hoffman, Emaan Atif, Khalid Shah, Filippo Rossignoli

An inducible RIPK3-driven necroptotic system enhances cancer cell–based immunotherapy and ensures safety

Journal of Clinical Investigation(2024)10.1172/jci181143

N/A

0DataRank · unranked

12 citations

Sarah Manoury-Battais, Nobuhiko Kanaya, Ioulia Vogiatzi, Paulo Borges, Sterre J. Kruize +6 more

Allogeneic stem cells engineered to release interferon β and scFv-PD1 target glioblastoma and alter the tumor microenvironment

Cytotherapy(2024)10.1016/j.jcyt.2024.05.012

N/A

0DataRank · unranked

7 citations

Lucia Moreno-Lama, A R Lehmann, Filippo Rossignoli, Jan Gettemans, Khalid Shah +1 more